Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Table 5 Model-simulated versus clinically- measured TTP

Simul. TTP	Clinic. TTP
Simul. TTP	0–90 days	90–150 days	150–365 days	No progressive disease during follow-up
0–90 days	8 (14.8%)	0 (0%)	2 (3.7%)	0 (0%)
90–150 days	0 (0%)	3 (5.6%)	0 (0%)	0 (0%)
150–365 days	0 (0%)	0 (0%)	2 (3.7%)	0 (0%)
No progressive disease during follow-up	2 (3.7%)	1 (1.85%)	1 (1.85%)	35 (64.8%)

The simulated TTP (Simul.) was obtained by fitting the simulations of the mathematical model in Eq. (1) to the clinical results (Clinic.). The cells in the table include the number of cases and the percentage of the total number of patients in the cohort, (in brackets; N = 54), which satisfy one of the six possible outcomes described in the “Methods” section. The italicized numbers represent the number of cases, for which the algorithm correctly predicted whether progression will occur, and correctly predicted the time interval during which progression would occur; Cohen’s κ = 0.773

ISSN: 1479-5876